Related Experiment Videos
Thrombolysis utilisation in acute myocardial infarction in Bahrain
A K Chawla1, C A Nambiar, A A Murad
1Salmaniya Medical Centre, Bahrain.
Insights
This study found that 57.9% of acute myocardial infarction patients received thrombolytic therapy. Improving patient education and ambulance services can increase this rate by reducing late presentations.
Area of Science:
- Cardiology
- Emergency Medicine
- Public Health
Background:
- Acute myocardial infarction (AMI) requires timely intervention.
- Thrombolytic therapy is a critical treatment for AMI.
- Understanding treatment utilization and barriers is essential for improving patient outcomes.
Purpose of the Study:
- To determine the utilization rate of thrombolytic therapy in AMI patients.
- To identify reasons for exclusion from thrombolytic therapy.
- To assess potential areas for improving thrombolytic therapy administration.
Main Methods:
- Retrospective study of 114 consecutive AMI patients.
- Analysis of patient records from the Accident and Emergency department.
- Categorization of patients based on thrombolytic therapy administration and exclusion criteria.
Main Results:
- 66 patients (57.9%) received thrombolysis (streptokinase or tissue plasminogen activator).
- 48 patients (42.1%) were excluded.
- Exclusion reasons included delayed presentation (23.7%), advanced age, and other contraindications.
Conclusions:
- Thrombolysis utilization in AMI at this center is high compared to global rates.
- Reducing late presentations through health education and enhanced ambulance services can improve thrombolysis rates.
- Further efforts are needed to optimize thrombolytic therapy delivery for AMI patients.
Abstract:
We retrospectively studied 114 consecutive patients of acute myocardial infarction diagnosed in the Accident and Emergency department of our hospital, to determine the percentage of eligible patients who actually received thrombolytic therapy, the number of those excluded from receiving such therapy and the various exclusion criteria. We found that 66 patients (57.9%) received thrombolysis with either streptokinase or tissue plasminogen activator (tPA). The remaining 48 (42.1%) were excluded because of delayed presentation to hospital after the onset of symptoms (23.7%), old age or other contraindications. Although the percentage of thrombolysis utilisation in acute myocardial infarction in our centre is much higher as compared to others in the world, we find that there is a scope for improving these figures by reducing the number of patients excluded because of late presentation through health education and improved utilisation of ambulance services.